Artigo de periodico

Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics (2022)

• Authors:
  • Pauli, Ivani
  • Rezende Junior, Celso de Oliveira
  • Slafer, Brian W.
  • Dessoy, Marco A.
  • Souza, Mariana Laureano de
  • Ferreira, Leonardo Luiz Gomes
  • Adjanohun, Abraham L. M.
  • Ferreira, Rafaela S.
  • Magalhães, Luma Godoy
  • Krogh, Renata
  • Duarte, Simone Michelan
  • Del Pintor, Ricardo Vaz
  • Silva, Fernando B. R. da
  • Cruz, Fabio C.
  • Dias, Luiz C.
  • Andricopulo, Adriano Defini
• USP affiliated authors: ANDRICOPULO, ADRIANO DEFINI - IFSC ; ANDRICOPULO, RENATA KROGH - IFSC ; DUARTE, SIMONE MICHELAN - IFSC ; PAULI, IVANÍ - IFSC ; SOUZA, MARIANA LAUREANO DE - IFSC ; FERREIRA, LEONARDO LUIZ GOMES - IFSC ; MAGALHÃES, LUMA GODOY - IFSC
• Unidade: IFSC
• DOI: 10.3389/fphar.2021.774069
• Subjects: DOENÇA DE CHAGAS; TRYPANOSOMA CRUZI; QUÍMICA MÉDICA; MODELAGEM MOLECULAR; PLANEJAMENTO DE FÁRMACOS
• Keywords: Chagas disease; Cruzain; Medicinal chemistry; Drug design; Multiparameter optimization; Pharmacokinetics; Molecular modeling
• Agências de fomento:
  • Financiamento CNPq
  • Financiamento CAPES
  • Financiamento FAPESP
  • Financiamento CEPID-FAPESP
• Language: Inglês
• Imprenta:
  • Publisher place: Lausanne
  • Date published: 2022
• Source:
  • Título: Frontiers in Pharmacology
  • ISSN: 1663-9812
  • Volume/Número/Paginação/Ano: v. 12, p. 774069-1-774069-21 + supplementary material, Jan. 2022


Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).

Status:

Artigo publicado em periódico de acesso aberto (Gold Open Access)

Versão do Documento:

Versão publicada (Published version)

Acessar versão aberta:

• PDF de acesso aberto

Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.

---

Download do texto completo

Tipo	Nome	Link
	PROD032730_3062985.pdf	Direct link

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  PAULI, Ivani et al. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, v. 12, n. Ja 2022, p. 774069-1-774069-21 + supplementary material, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2021.774069. Acesso em: 01 abr. 2026.

• APA

  Pauli, I., Rezende Junior, C. de O., Slafer, B. W., Dessoy, M. A., Souza, M. L. de, Ferreira, L. L. G., et al. (2022). Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, 12( Ja 2022), 774069-1-774069-21 + supplementary material. doi:10.3389/fphar.2021.774069

• NLM

  Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Krogh R, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2026 abr. 01 ] Available from: https://doi.org/10.3389/fphar.2021.774069

• Vancouver

  Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Krogh R, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2026 abr. 01 ] Available from: https://doi.org/10.3389/fphar.2021.774069

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Structure-based and molecular modeling studies for the discovery of cyclic imides as reversible cruzain inhibitors with potent anti-Trypanosoma cruzi activity
• Carbamoylimidazoles as potent cruzain inhibitors with in vitro and in vivo trypanocidal activity: a structure-based drug design approach
• Discovery of potent, reversible, and competitive cruzain inhibitors with trypanocidal activity: a structure-based drug design approach
• Antitrypanosomal aminobenzimidazoles: hit to lead expansion of new chemical entities against Trypanosoma cruzi and Leishmania infantum
• SAR studies on a series of reversible competitive inhibitors of cruzain from Trypanosoma cruzi
• Convergent synthesis of proline-functionalized pyrazolopyrimidines as anti-T. cruzi bioactive compounds
• Hit-to-lead for Chagas disease: lessons learned with Benzoxazinone series
• Indoles hit-to-lead for chagas disease: lessons learned within the LOLA consortium
• Synthesis and anti-trypanosoma cruzi activity of 3-cyanopyridine derivatives
• Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids